Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments
- PMID: 37321860
- PMCID: PMC10595024
- DOI: 10.1124/pharmrev.121.000506
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments
Erratum in
-
Correction to "Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments".Pharmacol Rev. 2023 Dec 15;76(1):195. doi: 10.1124/pharmrev.121.000506err. Pharmacol Rev. 2023. PMID: 38101935 Free PMC article. No abstract available.
Abstract
Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification of oxycodone, it was not until the 1990s that clinical studies began to explore its analgesic efficacy. These studies were followed by the pursuit of several preclinical studies to examine the analgesic effects and abuse liability of oxycodone in laboratory animals and the subjective effects in human volunteers. For a number of years oxycodone was at the forefront of the opioid crisis, playing a significant role in contributing to opioid misuse and abuse, with suggestions that it led to transitioning to other opioids. Several concerns were expressed as early as the 1940s that oxycodone had significant abuse potential similar to heroin and morphine. Both animal and human abuse liability studies have confirmed, and in some cases amplified, these early warnings. Despite sharing a similar structure with morphine and pharmacological actions also mediated by the μ-opioid receptor, there are several differences in the pharmacology and neurobiology of oxycodone. The data that have emerged from the many efforts to analyze the pharmacological and molecular mechanism of oxycodone have generated considerable insight into its many actions, reviewed here, which, in turn, have provided new information on opioid receptor pharmacology. SIGNIFICANCE STATEMENT: Oxycodone, a μ-opioid receptor agonist, was synthesized in 1916 and introduced into clinical use in Germany in 1917. It has been studied extensively as a therapeutic analgesic for acute and chronic neuropathic pain as an alternative to morphine. Oxycodone emerged as a drug with widespread abuse. This article brings together an integrated, detailed review of the pharmacology of oxycodone, preclinical and clinical studies of pain and abuse, and recent advances to identify potential opioid analgesics without abuse liability.
Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics.
Similar articles
-
Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.Cell Mol Neurobiol. 2021 Jul;41(5):899-926. doi: 10.1007/s10571-020-01013-y. Epub 2020 Nov 27. Cell Mol Neurobiol. 2021. PMID: 33245509 Free PMC article. Review.
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?Expert Opin Drug Saf. 2014 Feb;13(2):181-90. doi: 10.1517/14740338.2013.841136. Epub 2013 Nov 11. Expert Opin Drug Saf. 2014. PMID: 24206269 Review.
-
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.Psychopharmacology (Berl). 2010 Jul;210(4):471-80. doi: 10.1007/s00213-010-1838-3. Epub 2010 Apr 13. Psychopharmacology (Berl). 2010. PMID: 20386884 Free PMC article. Clinical Trial.
-
Nociceptin/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL/6 mice.Drug Alcohol Depend. 2018 Jun 1;187:335-342. doi: 10.1016/j.drugalcdep.2018.02.035. Epub 2018 Apr 15. Drug Alcohol Depend. 2018. PMID: 29705547
Cited by
-
Impact of oxycodone for the treatment of acute postoperative pain in cesarean section: A review.Medicine (Baltimore). 2025 Feb 21;104(8):e41645. doi: 10.1097/MD.0000000000041645. Medicine (Baltimore). 2025. PMID: 39993082 Free PMC article. Review.
-
Oxycodone, an opioid like the others?Front Psychiatry. 2023 Dec 13;14:1229439. doi: 10.3389/fpsyt.2023.1229439. eCollection 2023. Front Psychiatry. 2023. PMID: 38152360 Free PMC article. Review.
-
Oxycodone vs the Combination of Fentanyl and Remifentanil for General Anesthesia in Laparoscopic Uterine Myomas Surgery: A Prospective, Randomized, Controlled Study.Drug Des Devel Ther. 2025 Jun 9;19:4979-4990. doi: 10.2147/DDDT.S524102. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40521011 Free PMC article. Clinical Trial.
-
[Clinical pharmacology of opioid analgesics].Schmerz. 2025 Aug;39(4):287-300. doi: 10.1007/s00482-025-00880-y. Epub 2025 Apr 9. Schmerz. 2025. PMID: 40202585 Review. German.
-
Quantification of observable behaviors following oral administration of oxycodone and nalfurafine in male rhesus monkeys.Drug Alcohol Depend. 2023 Nov 1;252:110953. doi: 10.1016/j.drugalcdep.2023.110953. Epub 2023 Sep 4. Drug Alcohol Depend. 2023. PMID: 37734282 Free PMC article.
References
-
- Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL (2011) Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 90:844–851. - PubMed
-
- Aceto MD, Kipps BR, Harris LS, Bowman ER (2002) Updated studies on oxycodone, the active ingredient of the controlled-release formulation of oxycontin. Drug Alcohol Depend 66:S2.
-
- Alles SRA, Smith PA (2018) Etiology and pharmacology of neuropathic pain. Pharmacol Rev 70:315–347. - PubMed
-
- Altarifi AA, David B, Muchhala KH, Blough BE, Akbarali H, Negus SS (2017) Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol 31:730–739. - PMC - PubMed
-
- Altshuler RD, Yang ES, Garcia KT, Davis IR, Olaniran A, Haile M, Razavi S, Li X (2021) Role of orbitofrontal cortex in incubation of oxycodone craving in male rats. Addict Biol 26:e12927. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials